Literature DB >> 10049297

Ketolide treatment of Haemophilus influenzae experimental pneumonia.

K E Piper1, M S Rouse, J M Steckelberg, W R Wilson, R Patel.   

Abstract

The MICs of HMR 3004 and HMR 3647 at which 90% of beta-lactamase-producing Haemophilus influenzae isolates were inhibited were 4 and 2 micrograms/ml, respectively. Both HMR 3004 and HMR 3647 were active against beta-lactamase-producing H. influenzae in a murine model of experimental pneumonia. As assessed by pulmonary clearance of H. influenzae, HMR 3004 was more effective (P < 0.05) than was azithromycin, ciprofloxacin, clarithromycin, erythromycin A, pristinamycin, or HMR 3647 in this model.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10049297      PMCID： PMC89190     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  In vitro activity of the new ketolide HMR 3004 compared to an azalide and macrolides against Streptococcus pneumoniae and Haemophilus influenzae.

Authors:  A L Barry; P C Fuchs; S D Brown
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-10       Impact factor: 3.267

2.  Antibacterial activity of RU 64004 (HMR 3004), a novel ketolide derivative active against respiratory pathogens.

Authors:  C Agouridas; A Bonnefoy; J F Chantot
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

3.  A 1994-95 survey of Haemophilus influenzae susceptibility to ten orally administered agents. A 187 clinical laboratory center sample in the United States.

Authors:  R N Jones; M R Jacobs; J A Washington; M A Pfaller
Journal:  Diagn Microbiol Infect Dis       Date:  1997-03       Impact factor: 2.803

4.  Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group.

Authors:  C Thornsberry; P Ogilvie; J Kahn; Y Mauriz
Journal:  Diagn Microbiol Infect Dis       Date:  1997-12       Impact factor: 2.803

5.  In vitro evaluation of a novel ketolide antimicrobial agent, RU-64004.

Authors:  C Jamjian; D J Biedenbach; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

6.  Pharmacodynamic properties of HMR 3647, a novel ketolide, on respiratory pathogens, enterococci and Bacteroides fragilis demonstrated by studies of time-kill kinetics and postantibiotic effect.

Authors:  F J Boswell; J M Andrews; R Wise
Journal:  J Antimicrob Chemother       Date:  1998-02       Impact factor: 5.790

7.  Cellular accumulation of the new ketolide RU 64004 by human neutrophils: comparison with that of azithromycin and roxithromycin.

Authors:  D Vazifeh; H Abdelghaffar; M T Labro
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

8.  Experimental pneumonia due to Haemophilus influenzae: observations on pathogenesis and treatment.

Authors:  A L Esposito; J E Pennington
Journal:  J Infect Dis       Date:  1984-05       Impact factor: 5.226

9.  In vitro activities of the ketolide HMR 3647 against recent gram-positive clinical isolates and Haemophilus influenzae.

Authors:  A L Barry; P C Fuchs; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

10.  Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains.

Authors:  D J Biedenbach; M S Barrett; R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  1998-06       Impact factor: 2.803
  10 in total
  11 in total

1.  Intrapulmonary pharmacokinetics of telithromycin, a new ketolide, in healthy Japanese volunteers.

Authors:  Jun-Ichi Kadota; Yuji Ishimatsu; Tetsuji Iwashita; Yuichi Matsubara; Kazunori Tomono; Masao Tateno; Roza Ishihara; Claudette Muller-Serieys; Shigeru Kohno
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

2.  In vivo efficacy of the new ketolide telithromycin (HMR 3647) in murine infection models.

Authors:  A Bonnefoy; M Guitton; C Delachaume; P Le Priol; A M Girard
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  In vitro activity of telithromycin (HMR3647), a new ketolide, against clinical isolates of Mycoplasma pneumoniae in Japan.

Authors:  T Yamaguchi; Y Hirakata; K Izumikawa; Y Miyazaki; S Maesaki; K Tomono; Y Yamada; S Kamihira; S Kohno
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

4.  Telithromycin.

Authors:  J A Balfour; D P Figgitt
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Efficacies of ABT-773, a new ketolide, against experimental bacterial infections.

Authors:  M J Mitten; J Meulbroek; M Nukkala; L Paige; K Jarvis; A Oleksijew; A Tovcimak; L Hernandez; J D Alder; P Ewing; Y S Or; Z Ma; A M Nilius; K Mollison; R K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

6.  Efficacy of telithromycin (HMR 3647) against enterococci in a mouse peritonitis model.

Authors:  K V Singh; K K Zscheck; B E Murray
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

7.  Kinetic study of the inflammatory response in Streptococcus pneumoniae experimental pneumonia treated with the ketolide HMR 3004.

Authors:  M Duong; M Simard; Y Bergeron; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

8.  Telithromycin treatment of chronic Chlamydia pneumoniae infection in C57BL/6J mice.

Authors:  Liisa Törmäkangas; Hannu Alakärppä; Denise Bem David; Maija Leinonen; Pekka Saikku
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

Review 9.  Telithromycin.

Authors:  Keri Wellington; Stuart Noble
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 10.  The ketolides: a critical review.

Authors:  George G Zhanel; Michael Walters; Ayman Noreddin; Lavern M Vercaigne; Aleksandra Wierzbowski; John M Embil; Alfred S Gin; Stephen Douthwaite; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.